Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin

Thrombosis Research

Volumn 119, Issue 4, 2007, Pages 517-524

  Takahashi, Shinichi ^a,b   Ushida, Miho ^a,b   Komine, Risa ^a   Shimizu, Aya ^a   Uchida, Toshihiro ^a,b   Ishihara, Hiroaki ^a,b   Shibano, Toshiro ^a,b   Watanabe, Gentaro ^c   Ikeda, Yasuo ^a   Murata, Mitsuru ^a  

^a KEIO UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c Medical Center   (Japan)

Author keywords

Adiponectin; Aspirin resistance; Diabetes mellitus; Hyperplatelet activity; PFA 100

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ADRENALIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; COLLAGEN; CREATININE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; RISTOCETIN; THROMBOXANE B2; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; DEVICE; DIABETES MELLITUS; DRUG EFFECT; DRUG RESPONSE; HEMOSTASIS; HUMAN; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADIPONECTIN; ADULT; ASPIRIN; BLOOD PLATELETS; DIABETES MELLITUS; DRUG RESISTANCE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 33846413188     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.04.004     Document Type: Article

References (35)

1. Awtry E.H., and Loscalzo J. Aspirin. Circulation 10 (2000) 1206-1218
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
4. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 12 (1994) 2331-2336
5. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
6. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
7. Buchanan M.R., and Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11 (1995) 221-227
8. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
9. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
10. McKee S.A., Sane D.C., and Deliargyris E.N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 88 (2002) 711-715
11. Weber A.A., Przytulski B., Schanz A., Hohlfeld T., and Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 13 (2002) 37-40
12. Cerletti C., Dell'Elba G., Manarini S., Pecce R., Di Castelnuovo A., Scorpiglione N., et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 42 (2003) 1059-1070
13. Benedek I.H., Joshi A.S., Pieniaszek H.J., King S.Y., and Kornhauser D.M. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35 (1995) 1181-1186
14. Gearing A.J., and Newman W. Circulating adhesion molecules in disease. Immunol Today 14 (1993) 506-512
15. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
16. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (2003) 2461-2468
17. Mammen E.F., Comp P.C., Gosselin R., Greenberg C., Hoots W.K., Kessler C.M., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 (1998) 195-202
18. Homoncik M., Jilma B., Hergovich N., Stohlawetz P., Panzer S., and Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83 (2000) 316-321
19. Favaloro E.J. Clinical application of the PFA-100®. Curr Opin Hematol 9 (2002) 407-415
20. Heilmann E.J., Kundu S.K., Sio R., Garcia C., Gomez R., and Christie D.J. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 87 (1997) 159-164
21. Swank R.L. Alteration of blood on storage: measurement of adhesiveness of "aging" platelets and leukocytes and their removal by filtration. N Engl J Med 265 (1961) 728-733
22. Tschritter O., Fritsche A., Thamer C., Haap M., Shirkavand F., Rahe S., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52 (2003) 239-243
23. Yamamoto Y., Hirose H., Saito I., Tomita M., Taniyama M., Matsubara K., et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103 (2002) 137-142
24. Kawasaki T., Ozeki Y., Igawa T., and Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31 (2000) 591-595
25. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
26. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
27. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
28. Kato H., Kashiwagi H., Shiraga M., Tadokoro S., Kamae T., Ujiie H., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26 (2006) 224-230
29. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113 (2004) 101-113
30. Mori T.A., Vandongen R., Douglas A.J., McCulloch R.K., and Burke V. Differential effect of aspirin on platelet aggregation in IDDM. Diabetes 4 (1992) 261-266
31. Watala C., Pluta J., Golanski J., Rozalski M., Czyz M., Trojanowski Z., et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83 (2005) 148-158
32. Colwell J.A., and Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26 (2003) 2181-2188
33. DiMinno G., Silver M.J., Cerbone A.M., and Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 6 (1986) 886-891
34. 2+ homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 280 (2001) H1480-H1489
35. Vinik A.I., Erbas T., Park T.S., Nolan R., and Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476-1485